These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 35478115)
1. Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma. Karakatsanis SJ; Bouzani M; Symeonidis A; Angelopoulou MK; Papageorgiou SG; Michail M; Gainaru G; Kourti G; Sachanas S; Kalpadakis C; Katodritou E; Leonidopoulou T; Kotsianidis I; Hatzimichael E; Kotsopoulou M; Dimou M; Variamis E; Boutsis D; Kanellias N; Dimopoulou MN; Michali E; Karianakis G; Tsirkinidis P; Vadikolia C; Poziopoulos C; Pigaditou A; Vrakidou E; Economopoulos T; Kyriazopoulou L; Siakantaris MP; Kyrtsonis MC; Anargyrou K; Papaioannou M; Hatjiharissi E; Vervessou E; Tsirogianni M; Palassopoulou M; Stefanoudaki E; Zikos P; Tsirigotis P; Tsourouflis G; Assimakopoulou T; Verrou E; Papadaki H; Lampropoulou P; Dimopoulos MA; Pappa V; Konstantopoulos K; Karmiris T; Roussou P; Panayiotidis P; Pangalis GA; Vassilakopoulos TP; In Vivo; 2022; 36(3):1302-1315. PubMed ID: 35478115 [TBL] [Abstract][Full Text] [Related]
2. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. Vassilakopoulos TP; Pangalis GA; Katsigiannis A; Papageorgiou SG; Constantinou N; Terpos E; Zorbala A; Vrakidou E; Repoussis P; Poziopoulos C; Galani Z; Dimopoulou MN; Kokoris SI; Sachanas S; Kalpadakis C; Dimitriadou EM; Siakantaris MP; Kyrtsonis MC; Dervenoulas J; Dimopoulos MA; Meletis J; Roussou P; Panayiotidis P; Beris P; Angelopoulou MK Oncologist; 2012; 17(2):239-49. PubMed ID: 22282906 [TBL] [Abstract][Full Text] [Related]
3. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Plosker GL; Figgitt DP Drugs; 2003; 63(8):803-43. PubMed ID: 12662126 [TBL] [Abstract][Full Text] [Related]
4. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Poeschel V; Held G; Ziepert M; Witzens-Harig M; Holte H; Thurner L; Borchmann P; Viardot A; Soekler M; Keller U; Schmidt C; Truemper L; Mahlberg R; Marks R; Hoeffkes HG; Metzner B; Dierlamm J; Frickhofen N; Haenel M; Neubauer A; Kneba M; Merli F; Tucci A; de Nully Brown P; Federico M; Lengfelder E; di Rocco A; Trappe R; Rosenwald A; Berdel C; Maisenhoelder M; Shpilberg O; Amam J; Christofyllakis K; Hartmann F; Murawski N; Stilgenbauer S; Nickelsen M; Wulf G; Glass B; Schmitz N; Altmann B; Loeffler M; Pfreundschuh M; ; Lancet; 2019 Dec; 394(10216):2271-2281. PubMed ID: 31868632 [TBL] [Abstract][Full Text] [Related]
5. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202 [TBL] [Abstract][Full Text] [Related]
6. Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP. Vassilakopoulos TP; Michail M; Papageorgiou S; Kourti G; Angelopoulou MK; Panitsas F; Sachanas S; Kalpadakis C; Katodritou E; Leonidopoulou T; Kotsianidis I; Hatzimichael E; Kotsopoulou M; Dimou M; Variamis E; Boutsis D; Terpos E; Dimopoulou MN; Karakatsanis S; Michalis E; Karianakis G; Tsirkinidis P; Vadikolia C; Poziopoulos C; Pigaditou A; Vrakidou E; Economopoulos T; Kyriazopoulou L; Siakantaris MP; Kyrtsonis MC; Symeonidis A; Anargyrou K; Papaioannou M; Hatjiharissi E; Vervessou E; Tsirogianni M; Palassopoulou M; Gainaru G; Stefanoudaki E; Zikos P; Tsirigotis P; Tsourouflis G; Assimakopoulou T; Konstantinidou P; A Papadaki H; Megalakaki K; Dimopoulos MA; Pappa V; Karmiris T; Roussou P; Panayiotidis P; Konstantopoulos K; Pangalis GA Oncologist; 2021 Jul; 26(7):597-609. PubMed ID: 33870594 [TBL] [Abstract][Full Text] [Related]
7. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461 [TBL] [Abstract][Full Text] [Related]
8. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial. Gleeson M; Hawkes EA; Cunningham D; Chadwick N; Counsell N; Lawrie A; Jack A; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford J; McMillan A; Davies J; Turner D; Kruger A; Johnson PW; Gambell J; Linch D Br J Haematol; 2016 Nov; 175(4):668-672. PubMed ID: 27477167 [TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies. Vassilakopoulos TP; Papageorgiou SG; Angelopoulou MK; Chatziioannou S; Prassopoulos V; Karakatsanis S; Arapaki M; Mellios Z; Sachanas S; Kalpadakis C; Katodritou E; Leonidopoulou T; Kotsianidis I; Hatzimichael E; Kotsopoulou M; Dimou M; Variamis E; Boutsis D; Terpos E; Michali E; Karianakis G; Tsirkinidis P; Vadikolia C; Poziopoulos C; Pigaditou A; Vrakidou E; Siakantaris MP; Kyrtsonis MC; Symeonidis A; Anargyrou K; Papaioannou M; Chatziharissi E; Vervessou E; Tsirogianni M; Palassopoulou M; Gainaru G; Mainta C; Tsirigotis P; Assimakopoulou T; Konstantinidou P; Papadaki H; Dimopoulos MA; Pappa V; Karmiris T; Roussou P; Datseris I; Panayiotidis P; Konstantopoulos K; Pangalis GA; Rondogianni P Ann Hematol; 2021 Sep; 100(9):2279-2292. PubMed ID: 33523289 [TBL] [Abstract][Full Text] [Related]
10. R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma. Messmer M; Tsai HL; Varadhan R; Swinnen LJ; Jones RJ; Ambinder RF; Shanbhag SP; Borowitz MJ; Wagner-Johnston N Leuk Lymphoma; 2019 May; 60(5):1261-1265. PubMed ID: 30656983 [TBL] [Abstract][Full Text] [Related]
11. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Todeschini G; Secchi S; Morra E; Vitolo U; Orlandi E; Pasini F; Gallo E; Ambrosetti A; Tecchio C; Tarella C; Gabbas A; Gallamini A; Gargantini L; Pizzuti M; Fioritoni G; Gottin L; Rossi G; Lazzarino M; Menestrina F; Paulli M; Palestro M; Cabras MG; Di Vito F; Pizzolo G Br J Cancer; 2004 Jan; 90(2):372-6. PubMed ID: 14735179 [TBL] [Abstract][Full Text] [Related]
12. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Savage KJ; Al-Rajhi N; Voss N; Paltiel C; Klasa R; Gascoyne RD; Connors JM Ann Oncol; 2006 Jan; 17(1):123-30. PubMed ID: 16236753 [TBL] [Abstract][Full Text] [Related]